News Nipocalimab's Unique Mechanism Gets Second Chance in RA Last updated: May 14, 2024 1:43 am admin Share 0 Min Read SHARE The trial proved that nipocalimab reduced IgG antibodies, including anti-citrullinated protein autoantibodies, but the primary endpoint was missed. Medscape Medical News Source link TAGGED:#cancer#dermatology#diabetes#fitness#health#medicine#neurology#nutrition#obesity#orthopedics#pediatrics#telemedicine#wellnessAlternative MedicineCardiovascularChildren's HealthChronic DiseasesClinical TrialsDentistryDietDrug ResearchExerciseGeriatricsGlobal HealthHealth InsuranceHealthcare IndustryHealthcare PolicyImmunologyInfectious DiseasesMedical EducationMedical EthicsMedical ResearchMedical TechnologyMen's HealthMental HealthNursingOccupational TherapyOptometryPharmaceuticalsPhysical TherapyPreventive CarePublic HealthRare DiseasesRehabilitationReproductive HealthSenior HealthSexual HealthSpeech TherapyVaccinesWomen's Health Share This Article Facebook Twitter Copy Link Print Search for: Recent Posts Long-term exposure to air pollution may increase infertility risk in men Missouri bird flu inquiry broadens to close contact of patient Gaza: Over 22 000 people with life changing injuries urgently need rehabilitation, WHO warns Antidepressants prescribed for pain in older adults despite weak evidence of effectiveness WHO adds MVA-BN vaccine to prequalification list as first vaccine against mpox Archives September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 Categories Articles News
